Acer Therapeutics Inc.

2.82-0.0200-0.70%Vol 24.32K1Y Perf 49.50%
Apr 23rd, 2021 10:57 DELAYED
BID2.80 ASK2.82
Open2.81 Previous Close2.84
Pre-Market- After-Market-
 - -%  - -
Target Price
10.00 
Analyst Rating
Moderate Buy 2.20
Potential %
250.88 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Market Cap40.35M 
Earnings Rating
Sell
Price Range Ratio 52W %
23.74 
Earnings Date
13th May 2021

Today's Price Range

2.802.86

52W Range

1.885.84

5 Year PE Ratio Range

-4.00-1.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
4.41%
1 Month
-18.39%
3 Months
-22.62%
6 Months
2.16%
1 Year
49.50%
3 Years
-85.22%
5 Years
-88.57%
10 Years
-99.57%

TickerPriceChg.Chg.%
ACER2.82-0.0200-0.70
AAPL133.701.76001.33
GOOG2 295.6127.69001.22
MSFT259.672.50000.97
XOM55.830.56001.01
WFC43.650.95002.22
JNJ165.860.68000.41
FB298.842.32000.78
GE13.550.14001.04
JPM149.792.42001.64
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.43-0.50-16.28
Q03 2020-0.44-0.51-15.91
Q02 2020-0.38-0.56-47.37
Q01 2020-0.40-0.49-22.50
Q04 2019-0.55-0.517.27
Q03 2019-0.55-0.525.45
Q02 2019-0.81-1.09-34.57
Q01 2019-0.87-0.799.20
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.410.00-
6/2021 QR-0.3512.50Positive
12/2021 FY-1.4114.55Positive
12/2022 FY-1.882.59Positive
Next Report Date13th May 2021
Estimated EPS Next Report-0.41
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume24.32K
Shares Outstanding14.31M
Trades Count101
Dollar Volume418.16K
Avg. Volume1.18M
Avg. Weekly Volume100.84K
Avg. Monthly Volume232.55K
Avg. Quarterly Volume867.06K

Acer Therapeutics Inc. (NASDAQ: ACER) stock closed at 2.84 per share at the end of the most recent trading day (a 2.16% change compared to the prior day closing price) with a volume of 91.91K shares and market capitalization of 40.35M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 18 people. Acer Therapeutics Inc. CEO is Chris Schelling.

The one-year performance of Acer Therapeutics Inc. stock is 49.5%, while year-to-date (YTD) performance is 8.4%. ACER stock has a five-year performance of -88.57%. Its 52-week range is between 1.88 and 5.84, which gives ACER stock a 52-week price range ratio of 23.74%

Acer Therapeutics Inc. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 4.73, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -120.50%, a ROC of -131.10% and a ROE of -162.17%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Acer Therapeutics Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.41 for the next earnings report. Acer Therapeutics Inc.’s next earnings report date is 13th May 2021.

The consensus rating of Wall Street analysts for Acer Therapeutics Inc. is Moderate Buy (2.2), with a target price of $10, which is +250.88% compared to the current price. The earnings rating for Acer Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Acer Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Acer Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.92, ATR14 : 0.27, CCI20 : -74.07, Chaikin Money Flow : 0.00, MACD : -0.18, Money Flow Index : 43.11, ROC : -9.27, RSI : 43.05, STOCH (14,3) : 40.00, STOCH RSI : 1.00, UO : 44.47, Williams %R : -60.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Acer Therapeutics Inc. in the last 12-months were: Chris Schelling (Buy at a value of $500 000), Donald R. Joseph (Buy at a value of $49 998), John M. Dunn (Buy at a value of $74 998), Stephen Aselage (Buy at a value of $157 500)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (40.00 %)
2 (40.00 %)
2 (40.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (60.00 %)
3 (60.00 %)
3 (60.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.20
Moderate Buy
2.20
Moderate Buy
2.20

Acer Therapeutics Inc.

Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.

CEO: Chris Schelling

Telephone: +1 844 902-6100

Address: 300 Washington Street, Newton 02458, MA, US

Number of employees: 18

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

71%29%

Bearish Bullish

65%35%

Bearish Bullish

50%50%

News

Stocktwits